DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Finkel R, Wong B, Bushby K , et al.
Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD).
Neuromuscul Disord 2010;
20: 656-657
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.